CRL vs UHS
Charles River Laboratories vs Universal Health Services — AI-powered side-by-side comparison
CRL
Charles River Laboratories
61
Buy
VS
UHS
Universal Health Services
66
Buy
| Metric | CRL | UHS |
|---|
| AI Score |
61
|
66
|
| Price |
$297.55
|
$175.75
|
| P/E Ratio |
-61.69×
|
7.15×
|
| ROE |
-4.6%
|
20.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
32.2%
|
90.7%
|
| Debt / Equity |
1.07×
|
0.70×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
79.8
|
67.6
|
| Beta |
1.376
|
1.063
|
| Expected Upside |
+1.4%
|
+38.3%
|
AI Committee View
Current Innellis committee reasoning for CRL versus UHS.
UHS leads by 5 points.
UHS scores 66/100 (Buy) versus CRL at 61/100 (Buy).
CRL Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 5 consecutive earnings beats -- consistent execution. Risk Analyst remains cautious — bollinger bandwidth of 35.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 80 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 35.8% signals elevated volatility — Risk
UHS Committee View
80% agreement
5 analysts
The primary driver is eps growing 29.4% yoy. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- P/E of 6.8 is inexpensive for the broad market — Value
- ROE of 20.8% shows genuine earnings power backing the valuation — Value
- EPS growing 29.4% YoY — Growth
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.